Major Indian pharmaceutical companies experienced a significant rally on Monday, November 9, 2026, with Divis Laboratories, Gland Pharma, and Sai Life Sciences all reaching 52-week high share prices. This surge was primarily fueled by robust Q2 earnings reported by Divis Laboratories, which subsequently boosted investor confidence across the pharma sector.
Divis Laboratories Leads the Charge with Strong Q2 Performance
Divis Laboratories shares hit a 52-week high of Rs 11,818, a substantial increase from its previous close of Rs 11,080. The company's market capitalization climbed to Rs 3.07 lakh crore. The stock saw an intraday rise of 7%, extending its gains to 15% over two sessions following the announcement of its Q2 earnings on November 7.
The strong performance was underpinned by impressive financial results for the second quarter. Divis Laboratories reported a 64% increase in net profit, reaching Rs 1127 crore. Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) also saw a significant jump of 76%, totaling Rs 1,566 crore compared to Rs 888 crore in the same period last year. The EBITDA margin expanded notably to 42.6% from 32.7% year-on-year, indicating improved operational efficiency.
Gland Pharma and Sai Life Sciences Follow Suit
Buoyed by the positive sentiment from Divis Labs' earnings, other pharmaceutical firms also saw their shares rally. Gland Pharma's stock reached its own 52-week high, climbing 8% to Rs 3372 from its previous close of Rs 3126.15. This pushed the company's market cap to Rs 55,227 crore.
Gland Pharma also reported strong Q2 results, with net profit rising 58.2% year-on-year to Rs 291 crore, up from Rs 184 crore in the corresponding period last year. Revenue increased by 23.3% to Rs 1,834 crore. The company's EBITDA grew 54.1% to Rs 484 crore, and its EBITDA margin expanded to 26.4% from 21.1% a year ago, reflecting solid financial health.
Sai Life Sciences shares likewise surged to a 52-week high, rising 9% to Rs 1697.70. The firm's market capitalization reached Rs 38,472 crore, indicating broad-based positive investor reaction across the Indian pharmaceutical sector following these strong quarterly performances.